MONALISA® Mild Type with Lidocaine – 1 × 1ml *SALE*

MONALISA® Mild Type with Lidocaine – 1 × 1ml

Product Overview

MONALISA® Mild Type with Lidocaine is a professional cross-linked Hyaluronic Acid (HA) dermal filler developed for moderate wrinkle correction, natural facial volume enhancement, lip contouring and soft tissue augmentation.

Manufactured by GENOSS in South Korea, MONALISA® Mild Type contains 24mg/ml cross-linked Hyaluronic Acid and 0.3% Lidocaine.

Its balanced gel characteristics are designed to provide smooth tissue integration, controlled volumisation and natural-looking correction in facial areas requiring greater support than a fine-line filler without the firmer structural properties of a deeper volumising formulation.

MONALISA® Mild Type is positioned between the softer and firmer products within the MONALISA® dermal filler range. Its 400µm particle specification is designed to provide a balance of volume, flexibility and tissue support for appropriately selected facial treatments.

The cross-linked HA gel provides an immediate volumising and wrinkle-correcting effect following appropriate placement. Hyaluronic Acid also attracts and retains water within the tissue, helping support hydration and smoothness.

The formulation incorporates 0.3% Lidocaine, a local anaesthetic intended to help reduce injection-related discomfort and improve patient comfort during treatment.

Unlike skin boosters or regenerative Polynucleotide products, MONALISA® Mild Type is a structural Hyaluronic Acid dermal filler designed primarily for wrinkle correction, soft tissue augmentation and facial volume enhancement.

Pack Contents

Each pack contains:

• 1 × 1ml pre-filled syringe of MONALISA® Mild Type with Lidocaine

• Cross-linked Hyaluronic Acid: 24mg/ml

• Lidocaine: 0.3%

• Particle size: 400µm

• 2 × 27G needles, as commonly specified for this product

• Sterile, sealed professional-use packaging

Total Volume: 1ml

Always check the individual product packaging, supplied needle specification, manufacturer labelling and current Instructions for Use before administration.

Product CompositionCross-Linked Hyaluronic Acid – 24mg/ml

MONALISA® Mild Type contains highly purified cross-linked Hyaluronic Acid at a concentration of 24mg/ml.

The formulation is designed to support:

• Moderate wrinkle correction

• Soft tissue augmentation

• Facial volume restoration

• Lip contour enhancement

• Smooth tissue integration

• Controlled volumisation

• Gel stability

• Natural-looking correction

Cross-linking helps improve the stability and persistence of Hyaluronic Acid within the treated tissue compared with non-cross-linked formulations.

Lidocaine – 0.3%

The formulation contains 0.3% Lidocaine, a local anaesthetic incorporated into the gel to help reduce injection-related discomfort.

Patients with known hypersensitivity to Lidocaine or other relevant product components must be appropriately assessed before treatment.

400µm HA Particle Specification

Published MONALISA® product specifications identify Mild Type with a 400µm particle size.

This positions the product between finer and larger-particle formulations within the range, supporting its intended role as a balanced filler for moderate correction and natural facial volume enhancement.

MONALISA® Filler Technology

The MONALISA® dermal filler range is developed using GENOSS's Hyaluronic Acid manufacturing and cross-linking technology to create injectable HA formulations with different particle characteristics and tissue-placement profiles.

High-Purity Hyaluronic Acid

GENOSS describes the MONALISA® range as being manufactured using pharmaceutical-grade Hyaluronic Acid raw material to produce high-purity injectable gels.

Cross-Linked HA Technology

The cross-linked gel matrix is designed to support stability, structural performance and persistence within the treated tissue.

Controlled Particle Characteristics

Different MONALISA® formulations incorporate different particle characteristics to accommodate different treatment requirements.

Mild Type's 400µm particle specification positions it as a balanced formulation between softer and firmer products within the range.

Balanced Viscoelasticity

The formulation is designed to support smooth product delivery, controlled tissue integration and natural-looking volume correction.

Ergonomic Syringe Design

GENOSS describes its syringe grips and push rods as being designed to support controlled administration and consistent injection force.

Lidocaine-Containing Formulation

The inclusion of 0.3% Lidocaine is intended to improve patient comfort during treatment.

Balanced Facial Volume & Wrinkle Correction

MONALISA® Mild Type is designed for professional treatment of facial areas requiring moderate correction, soft tissue augmentation or natural-looking volume enhancement.

Its balanced cross-linked HA gel is intended to support:

• Correction of moderate facial wrinkles

• Lip contour enhancement

• Lip volume restoration

• Improvement in selected perioral lines

• Correction of appropriate facial folds

• Cheek volume enhancement where indicated

• Selected soft tissue volume restoration

• Facial contour refinement

Its formulation provides an intermediate option within the MONALISA® range, offering greater support than a softer fine-line product while maintaining greater flexibility than a firmer structural filler.

The suitability of any treatment area must always be confirmed against the manufacturer's current Instructions for Use.

Key Benefits

• Professional cross-linked Hyaluronic Acid dermal filler

• 24mg/ml HA concentration

• 0.3% Lidocaine

• 400µm particle specification

• Balanced gel characteristics

• Designed for moderate wrinkle correction

• Supports natural facial volume enhancement

• Suitable for appropriate lip contouring protocols

• Supports lip volume restoration

• May improve the appearance of selected perioral lines

• Supports correction of moderate facial folds

• May support cheek volume enhancement where clinically appropriate

• Provides immediate correction following appropriate placement

• Designed for smooth tissue integration

• Cross-linked formulation supports gel stability

• Manufactured using pharmaceutical-grade Hyaluronic Acid

• Lidocaine-containing formulation helps improve treatment comfort

• Ergonomic syringe design supports controlled product delivery

• Supplied in a 1ml pre-filled syringe

• Intended for appropriately qualified professional use

Common Treatment Areas

MONALISA® Mild Type may be selected for facial areas requiring moderate correction or natural-looking soft tissue augmentation.

Potential applications described in the supplied product information include:

• Lips

• Lip contour

• Lip volume enhancement

• Perioral lines

• Moderate facial wrinkles

• Marionette lines

• Nasolabial folds where appropriate

• Cheek volume enhancement

• Selected areas of facial volume loss

• Facial contour refinement

• Appropriate soft tissue augmentation procedures

Published MONALISA® product information also references forehead lines as a potential application.

However, treatment within higher-risk anatomical areas requires particular care and should only be considered where supported by the manufacturer's current Instructions for Use and the practitioner's training and competence.

Treatment suitability must always be determined following comprehensive assessment of facial anatomy, vascular structures, tissue characteristics and individual treatment objectives.

MONALISA® Mild Type vs Hard Type

Although both formulations contain cross-linked Hyaluronic Acid, they are positioned for different treatment requirements.

MONALISA® Mild Type

Designed primarily for:

• Moderate wrinkle correction

• Lip contour and volume

• Natural-looking facial enhancement

• Selected perioral concerns

• Moderate soft tissue augmentation

• Balanced volume and flexibility

Particle Specification: 400µm

MONALISA® Hard Type

Positioned as a firmer structural formulation for treatment requirements involving:

• Deeper correction

• Greater structural support

• Facial volume restoration

• Chin contour enhancement

• Jawline definition

• Selected areas requiring greater projection

Product selection should always be based on the manufacturer's current indications, gel characteristics, patient anatomy and professional assessment rather than HA concentration alone.

Professional Treatment Considerations

MONALISA® Mild Type is intended for administration by appropriately qualified and trained professionals with suitable competence in dermal filler treatments and facial anatomy.

Treatment planning should include:

• Comprehensive patient consultation

• Review of medical history

• Assessment of facial anatomy

• Evaluation of soft tissue characteristics

• Assessment of existing facial volume and proportions

• Review of previous aesthetic treatments

• Assessment of contraindications

• Discussion of realistic treatment expectations

• Explanation of potential adverse effects and complications

• Appropriate documented informed consent

Published product specifications describe placement within the superficial dermis through to the middle layer of subcutaneous tissue.

The precise treatment depth and technique must always be determined according to the specific anatomical area, current manufacturer Instructions for Use and appropriate professional training.

Needle or cannula selection, product volume and placement must be individually determined by the treating practitioner.

MONALISA® Mild Type should not be administered using a generic injection protocol without appropriate consideration of individual facial and vascular anatomy.

Treatment Review & Maintenance

The supplied product information describes a treatment pathway involving an initial treatment followed by professional reassessment.

A clinical review may commonly be considered approximately 2–4 weeks following treatment, according to practitioner protocol and individual patient requirements.

Additional correction should only be considered following appropriate assessment.

Maintenance requirements will depend on:

• Treatment area

• Product persistence

• Individual anatomy

• Patient metabolism

• Facial movement

• Tissue characteristics

• Previous treatment response

• Individual aesthetic objectives

Treatment intervals and product volumes must always be determined through professional assessment and the manufacturer's current guidance.

Results & Longevity

MONALISA® Mild Type is designed to provide an immediate volumising and wrinkle-correcting effect following appropriate administration.

Potential treatment outcomes may include:

• Improved lip contour

• Enhanced lip volume

• Reduction in the appearance of moderate facial wrinkles

• Improved selected facial folds

• Restored soft tissue volume

• Improved facial contour

• Smoother-looking treated areas

• Natural-looking facial enhancement

Initial swelling may temporarily influence the appearance of the treated area and should be considered when assessing early results.

As treatment-related swelling subsides, the final contour may become more apparent.

Published MONALISA® product information references an approximate maintenance period of 6–12 months for Mild Type.

This is a reported estimate rather than a guaranteed duration.

Individual longevity may vary according to:

• Treatment area

• Product volume

• Administration technique

• Patient metabolism

• Facial movement

• Patient age

• Lifestyle factors

• Tissue characteristics

• Individual biological response

Maintenance treatment may be considered following professional reassessment where appropriate.

Storage & Handling

Store MONALISA® Mild Type according to the manufacturer's current storage recommendations.

To maintain product integrity:

• Keep the product within its original packaging until required.

• Follow the manufacturer's specified storage conditions.

• Protect from inappropriate environmental exposure.

• Inspect the syringe and packaging before use.

• Check the batch number and expiry date.

• Verify product authenticity and traceability.

• Do not use if the sterile packaging is damaged.

• Do not use if the syringe appears compromised.

• Do not use after the stated expiry date.

The product should be handled using appropriate aseptic procedures.

Each syringe is intended for single use only.

Important Information

MONALISA® Mild Type with Lidocaine is intended strictly for use by appropriately qualified and trained medical or aesthetic professionals.

Professional knowledge of the following is essential:

• Facial anatomy

• Facial vascular anatomy

• Dermal filler administration

• Appropriate treatment planes

• Patient selection

• Aseptic technique

• Complication prevention

• Vascular compromise recognition

• Emergency management

• Dermal filler complication management

Patient Assessment & Contraindications

Treatment should only proceed following a full patient consultation, medical assessment and appropriate informed consent.

Treatment suitability must be assessed according to the manufacturer's current Instructions for Use.

Factors requiring particular consideration include:

• Active infection or inflammation within the proposed treatment area

• Known hypersensitivity to Hyaluronic Acid

• Known hypersensitivity to Lidocaine or other product components

• Pregnancy or breastfeeding

• Relevant uncontrolled medical conditions

• Previous filler treatments within the proposed treatment area

• Other contraindications identified during professional assessment

This list is not exhaustive and does not replace the manufacturer's official contraindications.

Potential Side Effects

Temporary treatment-related effects may include:

• Redness

• Swelling

• Bruising

• Tenderness

• Localised discomfort

• Temporary firmness

• Injection-site sensitivity

• Localised irregularity

Serious Complications

More serious complications associated with injectable dermal filler procedures may include:

• Infection

• Vascular compromise or occlusion

• Tissue ischaemia or necrosis

• Delayed inflammatory reactions

• Nodules

• Product migration

• Persistent contour irregularities

• Visual impairment or blindness associated with vascular complications

Practitioners must be appropriately trained in the prevention, recognition and management of filler-related complications, including emergency escalation where required.

Patients should receive appropriate written aftercare information and clear instructions regarding symptoms requiring urgent medical attention.

Always consult the manufacturer's current Instructions for Use for complete indications, contraindications, precautions, warnings, administration guidance and potential adverse events.

Do not use if:

• The sterile packaging is damaged or compromised

• The syringe appears damaged

• The product has passed its expiry date

• Product integrity is in doubt

• Product authenticity cannot be verified

For appropriately qualified professional use only.